← All trials
NCT06003348
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2023
- Primary completion
- May 31, 2028
- Completion date
- Aug 31, 2028
- First posted
- Aug 21, 2023
- Last posted
- Oct 13, 2023
- Enrollment
- 25
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The University of Texas, DallasLead sponsor
- The University of Texas, DallasOverall official - principal investigator
- The University of Texas, DallasReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.